Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HNRNPK_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HNRNPK_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HNRNPK_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HNRNPK_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HNRNPK_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HNRNPK_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HNRNPK_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HNRNPK_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HNRNPK_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HNRNPK_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HNRNPK_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HNRNPK_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HNRNPK_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719318 | Prostate | BPH | intrinsic apoptotic signaling pathway | 110/3107 | 288/18723 | 7.36e-19 | 2.85e-16 | 110 |
GO:005068415 | Prostate | BPH | regulation of mRNA processing | 64/3107 | 137/18723 | 1.73e-16 | 3.82e-14 | 64 |
GO:000037517 | Prostate | BPH | RNA splicing, via transesterification reactions | 114/3107 | 324/18723 | 2.19e-16 | 4.53e-14 | 114 |
GO:000037717 | Prostate | BPH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:000039817 | Prostate | BPH | mRNA splicing, via spliceosome | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:200124218 | Prostate | BPH | regulation of intrinsic apoptotic signaling pathway | 70/3107 | 164/18723 | 2.34e-15 | 3.72e-13 | 70 |
GO:004802418 | Prostate | BPH | regulation of mRNA splicing, via spliceosome | 51/3107 | 101/18723 | 3.74e-15 | 5.26e-13 | 51 |
GO:007233118 | Prostate | BPH | signal transduction by p53 class mediator | 64/3107 | 163/18723 | 3.51e-12 | 2.82e-10 | 64 |
GO:003311918 | Prostate | BPH | negative regulation of RNA splicing | 18/3107 | 25/18723 | 1.28e-09 | 5.57e-08 | 18 |
GO:007233217 | Prostate | BPH | intrinsic apoptotic signaling pathway by p53 class mediator | 34/3107 | 76/18723 | 8.04e-09 | 2.77e-07 | 34 |
GO:190331218 | Prostate | BPH | negative regulation of mRNA metabolic process | 38/3107 | 92/18723 | 1.63e-08 | 5.11e-07 | 38 |
GO:190179618 | Prostate | BPH | regulation of signal transduction by p53 class mediator | 38/3107 | 93/18723 | 2.31e-08 | 6.99e-07 | 38 |
GO:00506868 | Prostate | BPH | negative regulation of mRNA processing | 17/3107 | 29/18723 | 3.61e-07 | 7.60e-06 | 17 |
GO:00480258 | Prostate | BPH | negative regulation of mRNA splicing, via spliceosome | 13/3107 | 20/18723 | 1.72e-06 | 2.88e-05 | 13 |
GO:003010010 | Prostate | BPH | regulation of endocytosis | 60/3107 | 211/18723 | 1.06e-05 | 1.45e-04 | 60 |
GO:000863016 | Prostate | BPH | intrinsic apoptotic signaling pathway in response to DNA damage | 34/3107 | 99/18723 | 1.29e-05 | 1.70e-04 | 34 |
GO:004277116 | Prostate | BPH | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 19/3107 | 43/18723 | 1.97e-05 | 2.42e-04 | 19 |
GO:00068989 | Prostate | BPH | receptor-mediated endocytosis | 66/3107 | 244/18723 | 2.34e-05 | 2.80e-04 | 66 |
GO:200102015 | Prostate | BPH | regulation of response to DNA damage stimulus | 60/3107 | 219/18723 | 3.58e-05 | 3.92e-04 | 60 |
GO:190225310 | Prostate | BPH | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 14/3107 | 29/18723 | 7.48e-05 | 7.24e-04 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPK | SNV | Missense_Mutation | novel | c.1120N>T | p.Ala374Ser | p.A374S | P61978 | protein_coding | tolerated(0.77) | benign(0.021) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
HNRNPK | SNV | Missense_Mutation | | c.224G>C | p.Ser75Thr | p.S75T | P61978 | protein_coding | tolerated(0.31) | benign(0.06) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HNRNPK | SNV | Missense_Mutation | novel | c.38N>G | p.Thr13Ser | p.T13S | P61978 | protein_coding | tolerated_low_confidence(0.09) | benign(0.202) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
HNRNPK | SNV | Missense_Mutation | | c.10N>A | p.Glu4Lys | p.E4K | P61978 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.669) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HNRNPK | SNV | Missense_Mutation | novel | c.731A>T | p.Asp244Val | p.D244V | P61978 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
HNRNPK | SNV | Missense_Mutation | | c.10G>A | p.Glu4Lys | p.E4K | P61978 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.669) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
HNRNPK | insertion | Nonsense_Mutation | novel | c.301_302insAATATCAGAATTGAAACAATTGGAGAAATTC | p.Leu101GlnfsTer5 | p.L101Qfs*5 | P61978 | protein_coding | | | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
HNRNPK | SNV | Missense_Mutation | novel | c.1144N>A | p.Asp382Asn | p.D382N | P61978 | protein_coding | deleterious(0.04) | possibly_damaging(0.501) | TCGA-GH-A9DA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPK | SNV | Missense_Mutation | novel | c.723G>T | p.Met241Ile | p.M241I | P61978 | protein_coding | tolerated(0.15) | benign(0.01) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HNRNPK | SNV | Missense_Mutation | | c.256N>A | p.Arg86Ser | p.R86S | P61978 | protein_coding | deleterious(0.02) | benign(0.053) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |